bibw 2992 Recently Published Documents

L’afatinib (BIBW 2992)

Revue de Pneumologie Clinique ◽

10.1016/j.pneumo.2014.03.002 ◽

2014 ◽

Vol 70 (5) ◽

pp. 279-285 ◽

Author(s):

N. Prim ◽

M. Fore ◽

B. Mennecier

Keyword(s):

Abstract OT1-1-16: LUX-Breast 1: Randomized, Phase III trial of afatinib (BIBW 2992) and vinorelbine vs. trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment*

10.1158/0008-5472.sabcs12-ot1-1-16 ◽

2012 ◽

Author(s):

B Xu ◽

S-A Im ◽

C-S Huang ◽

Y-H Im ◽

J Ro ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Phase Iii Trial ◽

Trastuzumab Treatment ◽

Abstract OT1-1-15: LUX-Breast 3: Randomized Phase II trial of afatinib (BIBW 2992) alone or with vinorelbine versus investigator's choice of treatment in patients (pts) with HER2-positive breast cancer (BC) with progressive brain metastases after trastuzumab and/or lapatinib-based therapy*

10.1158/0008-5472.sabcs12-ot1-1-15 ◽

2012 ◽

Author(s):

H Joensuu ◽

M Ould-Kaci

Keyword(s):

Breast Cancer ◽

Brain Metastases ◽

Phase Ii ◽

Phase Ii Trial ◽

Her2 Positive ◽

Bibw 2992 ◽

Her2 Positive Breast Cancer ◽

Randomized Phase Ii ◽

Choice Of Treatment ◽

Positive Breast Cancer

Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors

Investigational New Drugs ◽

10.1007/s10637-012-9880-0 ◽

2012 ◽

Vol 31 (3) ◽

pp. 734-741 ◽

Cited By ~ 23

Author(s):

A. H. Awada ◽

H. Dumez ◽

A. Hendlisz ◽

P. Wolter ◽

T. Besse-Hammer ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Advanced Solid Tumors ◽

Impact of EGFR Mutation Status on Clinical Benefit from BIBW 2992 in Patients (PTS) with Advanced Non-Small Cell Lung Cancer (NSCLC) Progressing After Chemotherapy (CTX) and Erlotinib (E) or Gefitinib (G) – A Single Center Experience

Annals of Oncology ◽

10.1016/s0923-7534(20)33801-1 ◽

2012 ◽

Vol 23 ◽

pp. ix437-ix438

Author(s):

J. Köhler ◽

K. Worm ◽

T.C. Gauler ◽

M. Hoiczyk ◽

D. Theegarten ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Clinical Benefit ◽

Egfr Mutation ◽

Small Cell ◽

Single Center ◽

Small Cell Lung ◽

Mutation Status ◽

Bibw 2992 ◽

Single Center Experience

Phase I Study of Afatinib (BIBW 2992), An Erbb Family Blocker Plus Nintedanib (BIBF 1120), A Triple Angiokinase Inhibitor, in Patients (PTS) With Advanced Solid Tumours

Annals of Oncology ◽

10.1016/s0923-7534(20)33075-1 ◽

2012 ◽

Vol 23 ◽

pp. ix155 ◽

Author(s):

J. Soria ◽

A. Hollebecque ◽

C. Massard ◽

E. Deutsch ◽

A. Varga ◽

...

Keyword(s):

Phase I ◽

Phase I Study ◽

Solid Tumours ◽

Erbb Family ◽

Bibw 2992 ◽

Erbb Family Blocker ◽

Bibf 1120

Phase I Safety and Tolerability of Once Daily Oral Afatinib (A) (BIBW 2992) in Combination with Gemcitabine (G) in Patients (PTS) with Advanced Solid Tumours

Annals of Oncology ◽

10.1016/s0923-7534(20)33039-8 ◽

2012 ◽

Vol 23 ◽

pp. ix165

Author(s):

S. Zanetta ◽

J. Bennouna ◽

N. Isambert ◽

H. De Mont-Serrat ◽

I. Tschoepe ◽

...

Keyword(s):

Phase I ◽

Solid Tumours ◽

Once Daily ◽

Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker

Journal of Pharmacology and Experimental Therapeutics ◽

10.1124/jpet.112.197756 ◽

2012 ◽

Vol 343 (2) ◽

pp. 342-350 ◽

Cited By ~ 499

Author(s):

Flavio Solca ◽

Goeran Dahl ◽

Andreas Zoephel ◽

Gerd Bader ◽

Michael Sanderson ◽

...

Keyword(s):

Cellular Activity ◽

Binding Properties ◽

Erbb Family ◽

Bibw 2992 ◽

Erbb Family Blocker ◽

Target Binding

Abstract 2753: The addition of low dose 17-DMAG to BIBW-2992 effectively inhibits lung cancer cells with acquired resistance by T790M mutation

10.1158/1538-7445.am2012-2753 ◽

2012 ◽

Author(s):

Jin Kyung Rho ◽

Yun Jung Choi ◽

Sun Ye Kim ◽

Chang-Min Choi ◽

Jae Cheol Lee

Keyword(s):

Lung Cancer ◽

Cancer Cells ◽

Low Dose ◽

Acquired Resistance ◽

Lung Cancer Cells ◽

T790m Mutation ◽